HSLV Q1 2026 Earnings Massive EPS Surprise Despite Stock Decline CTOR Q1 2026 Earnings Deep Losses and Negative Surprise as Company Remains PreRevenue RSVR Q1 2026 Earnings EPS Surpasses Estimates with 7857 Beat Fulcrum Therapeutics Q1 2026 Earnings Narrowed Loss Exceeds Analyst Expectations Teradyne Q1 2026 Earnings Strong EPS Beat Driven by Robust Demand in Semiconductor Test MBINL Q1 2026 Earnings EPS Beats Estimates by 502 Amid Strong Operational Performance